Tag: NYSEMKT:FCSC

Finance

Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Sorrento Therapeutics Inc (NASDAQ:SRNE) announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento’s pipeline also shows promise in anti-infectives and auto-immune diseases. Sorrento Therapeutics Inc … Continue reading Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Mark Doerr
Finance

Watch List: Aoxing Pharmaceutical Company (NYSEMKT:AXN), Hyperion Therapeutics Inc (NASDAQ:HPTX), Aerie Pharmaceuticals (NASDAQ:AERI), Fibrocell Science Inc (NYSEMKT:FCSC), Abaxis Inc (NASDAQ:ABAX)

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, on 14 May 2014 announced its financial and operational results for the three and nine month periods ended March 31, 2014. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May … Continue reading Watch List: Aoxing Pharmaceutical Company (NYSEMKT:AXN), Hyperion Therapeutics Inc (NASDAQ:HPTX), Aerie Pharmaceuticals (NASDAQ:AERI), Fibrocell Science Inc (NYSEMKT:FCSC), Abaxis Inc (NASDAQ:ABAX)

Jayne Crisman
Finance

Healthcare Losers: TearLab Corp (NASDAQ:TEAR), Galectin Therapeutics (NASDAQ:GALT), Fibrocell Science (NYSEMKT:FCSC), BioLife Solutions (NASDAQ:BLFS)

TearLab Corporation (NASDAQ:TEAR) expects to announce its Q1 2014 financial results after market closes on Thursday May 8, 2014. TearLab Corporation (NASDAQ:TEAR) is pleased to invite all willing participants in a conference call during which time financial results will be discussed. TearLab Corp (NASDAQ:TEAR) stock performance was -7.61% in last session and finished the day at $4.98. Traded volume was 779,893.00million shares in the last … Continue reading Healthcare Losers: TearLab Corp (NASDAQ:TEAR), Galectin Therapeutics (NASDAQ:GALT), Fibrocell Science (NYSEMKT:FCSC), BioLife Solutions (NASDAQ:BLFS)

Mark DeFrance